- Home
- BOW vs LBPH Comparison
BOW vs LBPH Comparison
Compare BOW & LBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOW
- LBPH
- Stock Information
- Founded
- BOW 2020
- LBPH 2020
- Country
- BOW United States
- LBPH United States
- Employees
- BOW N/A
- LBPH N/A
- Industry
- BOW Property-Casualty Insurers
- LBPH Biotechnology: Pharmaceutical Preparations
- Sector
- BOW Finance
- LBPH Health Care
- Exchange
- BOW Nasdaq
- LBPH Nasdaq
- Market Cap
- BOW 880.2M
- LBPH 810.3M
- IPO Year
- BOW 2024
- LBPH 2021
- Fundamental
- Price
- BOW $28.35
- LBPH $31.78
- Analyst Decision
- BOW Hold
- LBPH Strong Buy
- Analyst Count
- BOW 5
- LBPH 8
- Target Price
- BOW $29.20
- LBPH $53.38
- AVG Volume (30 Days)
- BOW 105.9K
- LBPH 536.6K
- Earning Date
- BOW 08-06-2024
- LBPH 10-31-2024
- Dividend Yield
- BOW N/A
- LBPH N/A
- EPS Growth
- BOW N/A
- LBPH N/A
- EPS
- BOW 1.04
- LBPH N/A
- Revenue
- BOW $348,467,000.00
- LBPH N/A
- Revenue This Year
- BOW N/A
- LBPH N/A
- Revenue Next Year
- BOW $24.23
- LBPH N/A
- P/E Ratio
- BOW $27.62
- LBPH N/A
- Revenue Growth
- BOW 51.06
- LBPH N/A
- 52 Week Low
- BOW $22.14
- LBPH $3.60
- 52 Week High
- BOW $32.55
- LBPH $40.48
- Technical
- Relative Strength Index (RSI)
- BOW N/A
- LBPH 48.72
- Support Level
- BOW N/A
- LBPH $33.20
- Resistance Level
- BOW N/A
- LBPH $34.80
- Average True Range (ATR)
- BOW 0.00
- LBPH 2.24
- MACD
- BOW 0.00
- LBPH -0.23
- Stochastic Oscillator
- BOW 0.00
- LBPH 25.56
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc is engaged in providing specialty P&C products. It is a specialty insurance group that generates revenues by underwriting and offering a variety of specialty insurance products to domestic markets through three distinct underwriting divisions: Casualty, Professional Liability and Healthcare. Casualty specialize in GL coverage for risks in the construction, distribution, heavy manufacturing, real estate and hospitality segments and also consider underwriting risks in a broader range of industries. Key revenue is generated from Casualty segment.
About LBPH Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.